Clinical experience of galantamine in dementia: A series of case reports

Current Medical Research and Opinion

Volumn 19, Issue 6, 2003, Pages 508-518

  Dale, Mark C ^a   Libretto, Susan E ^b   Patterson, C ^c   Anderson, J ^d   Choudhury, T ^e   McCafferty, F ^f   McWilliam, C ^g   Richardson, M ^h  

^a BLACKPOOL TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b Janssen Cilag Ltd   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d Ards Community Hospital   (United Kingdom)

^e Countess of Chester Hospital ^*  (United Kingdom)

^f ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^g Ribbleton Hospital   (United Kingdom)

^h NONE

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Dementias; Galantamine; Patient benefits

Indexed keywords

DOMPERIDONE; DONEPEZIL; GALANTAMINE; RISPERIDONE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CASE STUDY; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; COGNITION; DAILY LIFE ACTIVITY; DEMENTIA; DRUG MECHANISM; FEMALE; HUMAN; LEWY BODY; MALE; MULTIINFARCT DEMENTIA; NAUSEA; PARKINSON DISEASE; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DEMENTIA; FEMALE; GALANTAMINE; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS;

EID: 0141682155     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002054     Document Type: Article

References (38)

1. Hofman A, Rocca WA, Brayne C, Breteler MM, Clarke M, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol 1991;20:736-48
2. Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. Psychol Med 1998;28:319-35
3. Patterson CJ, Gauthier S, Bergman H, Cohen CA, Feightner JW, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can Med Assoc J 1999;160 (Suppl):S1-S15
4. McNamee P, Bond J, Buck D. Costs of dementia in England and Wales in the 21st century. Br J Psychiatry 2001;179:261-6
5. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049-51
6. Morriss RK, Rovner BW, German PS. Factors contributing to nursing home admission because of disruptive behaviour. Int J Geriatr Psychiatry 1996;11:243-9
7. Gallagher M, Colombo PJ. Aging: the cholinergic hypothesis of cognitive decline. Curr Opin Neurobiol 1995;5:161-8
8. Kasa P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer's disease. Prog Neurobiol 1997;52:511-35
9. Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 2000;113:199-206
10. Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001;16:653-66
11. Christie JE, Shering A, Ferguson J, Glen AI. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer pre-senile dementia. Br J Psychiatry 1981;138:46-50
12. Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48;736-42
13. Byrne GJA. Treatment of cognitive impairment in Alzheimer's disease. Aust J Hosp Pharm 1998;28:261-6
14. Weinstock M. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. Neurodegeneration 1995;4:349-56
15. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996;103:1211-20
16. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with (-) galanthamine at 2.3 Å resolution. FEBS Lett 1999;463:321-6
17. Storch A, Schrattenholz A, Cooper JC, Abdel Ghani EM, Gutbrod O, et al. Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists' on clonal rat pheochromocytoma cells. Eur J Pharmacol 1995;290:207-19
18. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psych 2000;71:589-95
19. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfield S, et al. A 5-month randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-76
20. Wilcock GK, Lileinfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. Galantamine Interantional-1 Study Group. BMJ 2000;321:1445-9
21. Rockwood K, Graham JE, Fay S. Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry 2002;73:500-7
22. Mohs RC, Ferris SH. Measuring response to treatment in Alzheimer's disease: what constitutes meaningful change? Int J Geriatr Psychopharmacol 1998;1 (Suppl):S7-S14
23. Gold L, Rayner I. Dealing with dementia. Pulse 2002;25:52-5
24. Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs Aging 2001;18:853-62
25. Rosler M, Anand R, Cicin-Sain A, Gauthiers S, Agid Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-60
26. Rasmusen L, Yan B, Robillard A, Dunbar F. Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clin Ther 2001;23 (Suppl A):A25-A30
27. Maelicke A. Pharmacokinetic rationale for switching from donepezil to galantamine. Clin Ther 2001;23 (Suppl A):A8-A12
28. Snorrason E, Stefansson JG. Galantamine hydrobromide in mania. Lancet 1991;337:557
29. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, et al. A randomised trial of risperidone, placebo, and haloperidol for behavioural symptoms of dementia. Neurology 1999;53:946-55
30. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, et al. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomised, double-blind trial. J Clin Psychiatry 1999;60:107-15
31. Maelicke A. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl™). Int J Clin Pract 2001;120 (Suppl):24-8
32. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-90
33. McKeith IG, Del Ser T, Spano P, Emre M, Wesnes K, et al Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo controlled international study. Lancet 2000;356:2031-6
34. Lebert F, Pasquier F, Souliez L, Petit H. Tacrine efficiency in Lewy body dementia. Int J Geriatr Psychiatry 1998;13:516-19
35. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998;10:229-38
36. MacLean LE, Collins CC, Byrne EJ. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriatr 2001;13:277-88
37. Teri L, Borson S, Kiyak HA, Yamagashi M. Behavioural disturbance, cognitive dysfunction and functional skill: prevalence and relationship in Alzheimer's disease. J Am Geriatr Soc 1989;37:109-16
38. Brodaty H, McGilchrist C, Harris L, Peters K. Time until institutionalisation and death in patients with dementia. Arch Neurol 1993;50:643-50